Human Proteinpedia as a Resource for Clinical Proteomics

Institute of Bioinformatics, International Tech Park, Bangalore 560 066, India.
Molecular &amp Cellular Proteomics (Impact Factor: 7.25). 07/2008; 7(10):2038-47. DOI: 10.1074/mcp.R800008-MCP200
Source: PubMed

ABSTRACT Clinical proteomics is an emerging field that deals with the use of proteomic technologies for medical applications. With a major objective of identifying proteins involved in pathological processes and as potential biomarkers, this field is already gaining momentum. Consequently, clinical proteomics data are being generated at a rapid pace, although mechanisms of sharing such data with the biomedical community lag far behind. Most of these data are either provided as supplementary information through journal web sites or directly made available by the authors through their own web resources. Integration of these data within a single resource that displays information in the context of individual proteins is likely to enhance the use of proteomic data in biomedical research. Human Proteinpedia is one such portal that unifies human proteomic data under a single banner. The goal of this resource is to ultimately capture and integrate all proteomic data obtained from individual studies on normal and diseased tissues. We anticipate that harnessing of these data will help prioritize experiments related to protein targets and also permit meta-analysis to uncover molecular signatures of disease. Finally, we encourage all biomedical investigators to maximize dissemination of their valuable proteomic data to rest of the community by active participation in existing repositories such as Human Proteinpedia.

  • Source
    • "Protein profiling can be performed on complex peptide or protein mixtures from whole or partially fractionated tissue extracts or biofluids such as serum (Gagnon et al., 2008; Cazares et al., 2008; Lopez et al., 2007), urine and cerebrospinal fluid, or directly on thin tissue sections (Chaurand et al., 2004; Yanagisawa et al., 2003). For the antibody-based profiling, the antibodies against predetermined protein lists that are important in a given biological process, pathway or clinical outcome are used to determine the protein signatures (Tong et al., 2008; Mathivanan and Pandey, 2008; Wang et al., 2005). The negative aspects of antibody-based Proteomics are that the assay is limited by the availability of antibodies and the need for having the prior knowledge of proteins of interest. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The advent of functional genomics has been greatly broadening our view and accelerating our way in numerous medical research fields. The complete genomic data acquired from the human genome project and the desperate clinical need of comprehensive analytical tools to study complex diseases, has allowed rapid evolution of genomic and proteomic technologies, speeding the rate and number of discoveries in new biomarkers. By jointly using genomics, proteomics and bioinformatics there is a great potential to make considerable contribution to biomarker identification and to revolutionize both the development of new therapies and drug development process.
    Toxicology Letters 11/2008; 186(1):45-51. DOI:10.1016/j.toxlet.2008.10.014 · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The sequencing of the human genome was an exceptional achievement, but it was not an end in itself as it set the foundation for building new knowledge in biology and medicine. The laborious, multifaceted science of drug discovery and development also draws tremendous benefits from mining the human genome and exploiting the large palette of genomic technologies. This article discusses how diverse genomic tools have been used to date and how they will continue to be utilized in the future to impact drug discovery and development. Integrating genomics across drug discovery and development will undoubtedly help to shorten timelines, increase success rates at all stages and ultimately bring the right drugs to the right patients at the right times.
    Toxicology Letters 10/2008; 186(1):9-12. DOI:10.1016/j.toxlet.2008.09.011 · 3.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Some mutations resulting in protein sequence change might be tightly related to certain human diseases by affecting its roles, such as sickle cell anemia. Until now several databases, such as PMD, OMIM and HGMD, have been developed, providing useful information about human disease-related mutation. Tandem mass spectrometry (MS) has been used for characterizing proteins in various conditions; however, there is no system in place for finding disease-related mutated proteins within the MS results. Here, a Systematical Platform for Identifying Mutated Proteins (SysPIMP; was developed to efficiently identify human disease-related mutated proteins within MS results. SysPIMP comprises of three layers: (i) a standardized data warehouse, (ii) a pipeline layer for maintaining human disease databases and X!Tandem and BLAST and (iii) a web-based interface. From OMIM AV part, PMD and SwissProt databases, 35,497 non-redundant human disease-related mutated sequences were collected with disease information described by OMIM terms. With the interfaces to browse sequences archived in SysPIMP, X!Tandem, an open source database-search engine used to identify proteins within MS data, was integrated into SysPIMP to help support the detection of potential human disease-related mutants in MS results. In addition, together with non-redundant disease-related mutated sequences, original non-mutated sequences are also provided in SysPIMP for comparative research. Based on this system, SysPIMP will be the platform for efficiently and intensively studying human diseases caused by mutation.
    Nucleic Acids Research 12/2008; 37(Database issue):D913-20. DOI:10.1093/nar/gkn848 · 9.11 Impact Factor
Show more


Available from